Letter of Intent
2010年5月11日 - 6:31PM
RNSを含む英国規制内ニュース (英語)
TIDMHML
RNS Number : 6906L
Henderson Morley PLC
11 May 2010
11 MAY 2010
HENDERSON MORLEY PLC
(AIM: HML)
UPDATE REGARDING LETTER OF INTENT
The Board of Henderson Morley plc ("Henderson Morley" or the "Company"), the AIM
quoted biotechnology company, today updates the market regarding the Letter of
Intent ("LOI") signed by specialist therapeutic drug development company, KMS
Therapeutics, ("KMS").
KMS remains committed to the LOI, which as previously stated, is in respect of
the intellectual property rights (IPR) of its ionic contra-viral therapy
("ICVT") human portfolio. On completion of the transaction, which is conditional
on satisfactory due diligence, KMS has agreed to pay Henderson Morley an
additional payment of not less than $250,000 in exchange for consultancy
services or other specialized work as directed by KMS, and agreed to by
Henderson Morley, to help accelerate the time to markets for the products.
Additionally, subsequent to the announcement on 12 March 2010, KMS has requested
an extension to the due diligence period to 14 July 2010 which Henderson Morley
has granted. All other points in the LOI remain unchanged.
Commenting Executive Chairman Andrew Knight said: "We are encouraged that KMS
has agreed to pay an additional minimum of $250,000, subject to completion of
the transaction, which further demonstrates their confidence in the ICVT
platform technology. They have also informed the Company that they now expect to
be in a position to complete the due diligence, and make the first milestone
payment by the extended date."
Martin Marino, VP of KMS Therapeutics added: "The due diligence is proceeding
well and we remain focussed on the completion of this agreement. We have also
now agreed a consultancy fee, payable to Henderson Morley, of not less than
$250,000, in recognition of the contribution it will make to the development
project. It is anticipated that Henderson Morley will commence its work
immediately after closing and that the first $250,000 will be earned within the
initial twelve month period."
-END-
Enquires
HENDERSON MORLEY PLC
0121 442 4600
Andrew Knight, Chairman
BISHOPSGATECOMMUNICATIONS LTD 0207 562
3350
Maxine Barnes
Gemma O'Hara
BREWIN DOLPHIN INVESTMENT BANKING 0845 213
4730
Neil Baldwin
RIVINGTON STREET CORPORATE FINANCE 0207 562 3380
Jon Levinson
Further information on Henderson Morley plc can be accessed through the
Company's website at www.henderson-morley.com
Notes to Editors
KMS is a specialist therapeutic drug development company that was established by
a number of former Merck Generics Senior Executives including Hank Klakurka,
former CEO, Steve Self, former Global R&D Director and Martin Marino, former
Chief Legal Counsel. This company's model takes high potential drug candidates
through clinical trials, regulatory and into production and sales. It currently
has four development projects in its pipeline, one of which is a respiratory
project and the other three are anti-infectives.
This information is provided by RNS
The company news service from the London Stock Exchange
END
LOIGCGDUCDBBGGB
Henderson Mrly. (LSE:HML)
過去 株価チャート
から 8 2024 まで 9 2024
Henderson Mrly. (LSE:HML)
過去 株価チャート
から 9 2023 まで 9 2024
Real-Time news about Henderson Mrly. (ロンドン証券取引所): 0 recent articles
その他のHenderson Morleyニュース記事